Multiple Ascending Dose (MAD)

Multiple Ascending Dose (MAD) studies are critical to evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of investigational therapies following repeated administration. CenExel supports sponsors with efficient MAD trial execution, generating the data needed to optimize dosing strategies and advance promising therapies through clinical development.

Partner With Us

Studies Conducted

Acute & post-surgical pain focus

0 +

Trial Participants

Enrolled in acute pain studies

0 +

Active Sites

Specialized research locations

Overview

Advancing Clinical Development Through MAD Studies

CenExel delivers comprehensive Multiple Ascending Dose study capabilities designed to support early-phase drug development programs. Our experienced clinical teams conduct carefully monitored repeated-dose studies that provide critical insights into drug accumulation, safety profiles, dose proportionality, and therapeutic potential.

We collaborate closely with sponsors to design flexible protocols, ensuring high-quality data collection while maintaining participant safety throughout each dosing cohort.

Conditions Covered

Acute Pain Conditions We Research

Our MAD study capabilities support a wide range of indications, including:

CNS Disorders

Psychiatry

Behavioral Health

Metabolic Diseases

Obesity

Diabetes

Inflammatory Disorders

Rare Diseases

Neurology

Cardiovascular Conditions

Our Approach

Why Sponsors Choose CenExel for MAD Studies

From dose escalation planning to data-driven decision-making, our MAD studies deliver operational excellence, scientific precision, and trusted results at every stage.

01

Experienced Early-Phase Teams

Dedicated research professionals with extensive experience conducting complex dose-escalation studies.

02

Advanced PK/PD Capabilities

Comprehensive pharmacokinetic and pharmacodynamic assessments supporting critical development decisions.

03

Real-Time Safety Monitoring

Continuous medical oversight and rapid safety review processes throughout dose escalation.

04

Flexible Study Execution

Scalable infrastructure designed to accommodate diverse protocols and evolving sponsor requirements.

Phase Coverage

Supported Trial Phases

We support Multiple Ascending Dose studies across early clinical development programs, providing reliable execution and actionable data.

Active across all phases

Phase I

Phase II

Phase III

Phase IV

Early Phase Clinical Development Excellence

CenExel's early-phase research teams provide extensive expertise in Multiple Ascending Dose study execution. Our investigators focus on participant safety, protocol compliance, biomarker integration, and high-quality PK/PD data collection to support informed dose escalation decisions and successful program advancement.

Explore task force